Chandola Rahul, Laing Bryce, Lien Dale, Mullen John
From the Division of Cardiovascular Surgery, University of Alberta, University of Alberta, Edmonton, Alberta T6G 2B7, Canada.
Exp Clin Transplant. 2018 Feb;16(1):75-80. doi: 10.6002/ect.2016.0289. Epub 2017 Oct 31.
We evaluated the incidence, clinical presentation, laboratory findings, possible causes, and outcomes associated with pneumatosis intestinalis in the setting of lung transplant.
A departmental database showed that, between October 2002 and August 2013, our institution performed 373 lung transplants. The database was queried for all patients who had pneumatosis intestinalis and/or pneumoperitoneum after lung transplant at our institution. For this retrospective chart review, information collected included demographics, baseline variables, symptoms, signs, laboratory parameters, radiologic work-up, medications, including immunosuppressants at presentation, progress and time to resolution, length of hospital stay, and postoperative complications, as well as short-term and midterm outcomes (up to 1 year).
The incidence of pneumatosis intestinalis was 2.68% (10/373 patients). Mean age of patients was 52.2 years (range, 34.9-67.9 y). Mean time for development of pneumatosis intestinalis after transplant was 352.8 days (range, 5-2495 d). Abdominal symptoms and signs were present in 6 patients (60%). The large bowel was the site of involvement in all but 1 patient, with predilection for ascending colon (80%) and transverse colon (90%) in most patients. High serum lactate levels were found in 2 patients, and both underwent bowel resection, with surgical specimens revealing evidence of ischemic changes in the gut. Mean dose of prednisone was 22 mg at the time of presentation (range, 0-60 mg). Mean hospital length of stay was 16.9 days (range, 0-40 d). Short-term survival was 100%. Midterm survival at the end of 1 year was 80%. Mean time for pneumatosis to resolve was 18 days (range, 14-35 d).
Pneumatosis intestinalis in bilateral lung transplant recipients can be treated with a minimal amount of imaging, and most patients can be treated conservatively. Survival outcomes are quite good, with 100% during the short term and 80% at 1 year in our series.
我们评估了肺移植患者中肠壁积气的发生率、临床表现、实验室检查结果、可能病因及预后。
科室数据库显示,2002年10月至2013年8月期间,我院共进行了373例肺移植手术。查询数据库以获取我院所有肺移植后发生肠壁积气和/或气腹的患者。对于此次回顾性病历审查,收集的信息包括人口统计学资料、基线变量、症状、体征、实验室参数、影像学检查、用药情况(包括就诊时的免疫抑制剂)、病情进展及缓解时间、住院时间、术后并发症以及短期和中期预后(最长1年)。
肠壁积气的发生率为2.68%(10/373例患者)。患者的平均年龄为52.2岁(范围34.9 - 67.9岁)。移植后发生肠壁积气的平均时间为352.8天(范围5 - 2495天)。6例患者(60%)出现腹部症状和体征。除1例患者外,所有患者的病变均累及大肠,大多数患者以升结肠(80%)和横结肠(90%)受累为主。2例患者血清乳酸水平升高,均接受了肠切除术,手术标本显示肠道存在缺血改变的证据。就诊时泼尼松的平均剂量为22 mg(范围0 - 60 mg)。平均住院时间为16.9天(范围0 - 40天)。短期生存率为100%。1年末的中期生存率为80%。肠壁积气缓解的平均时间为18天(范围14 - 35天)。
双侧肺移植受者的肠壁积气可以通过最少的影像学检查进行处理,大多数患者可采用保守治疗。生存预后相当良好,在我们的系列研究中,短期生存率为100%,1年生存率为80%。